Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

data evaluating the safety and performance of a bioabsorbable drug eluting coronary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has consistently been at the forefront of advances in interventional cardiology - from the early days of angioplasty to our continued success with bare metal stents and the market-leading XIENCE V drug eluting stent. Our bioabsorbable device is another example of scientific innovation leading to an interventional breakthrough," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Today's data publication in The Lancet confirms the promise our bioabsorbable device holds as a vasorestorative therapy for patients with coronary artery disease."

Abbott will begin enrolling patients in the second phase of its international ABSORB clinical trial in the first half of 2009.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the sten
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 The ... in collaboration with one of the leading academics in the ... (current world record holder in life extension for model animals ... into biology of aging and age-related diseases, primarily, around the ... work has just been published as "Stability analysis of a ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Oct. 5 Osseon Therapeutics, Inc. announced its ... North American Spine Society,s (NASS) annual meeting in ... facilitate treatment of vertebral compression fractures (VCFs) that ... fibrotic metastases.  The Osseoflex DR Steerable Bone Drill ...
... SUNNYVALE, Calif., Oct. 5 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today that the company was awarded a ... U.S. Government to be used toward further development of a ... grant will fund the development of a next generation, compact ...
Cached Medicine Technology:Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill 2Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:8/30/2015)... ... 2015 , ... Scientists in France say asbestos exposure may put workers at ... Mesothelioma has just posted an article on the new research. Click here to ... incidence among 2,024 French asbestos plant workers from 1978 to 2009. In addition to ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale Avene ... , “Before, a threshold of $49.00 was required to qualify for free standard shipping,” ... free standard shipping for customers regardless of the item’s selling price.” , With competitive ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... a small molecule that can turn the survival signal for ... molecule mimics the activity of Smac, a protein that triggers ... researchers say their findings suggest that Smac-mimetic compounds could be ... Such therapy may be less toxic to healthy cells than ...
... Zero In on Rac1, Rac2 Genes as ... Molecular Targets, ... of Cancer Cell, researchers at Cincinnati Children,s Hospital Medical,Center reported that they ... spread of chronic myelogenous leukemia,(CML) in mice. When these genes, Rac1 ...
... 12 The American Cancer Society,is looking for individuals ... personal interest in the battle against cancer to serve ... be funded by the,organization,s research and training grants. These ... such as having had a,family member with cancer, having ...
... Stock Exchange Symbol: AKL, MONTREAL, Nov. 12 ... development company focused on developing therapies for the,inhalation ... from,its pilot GHRH Phase II study. Within only ... significant stimulation of endogenous growth hormone (GH),secretion and ...
... International,Isotopes Inc. (OTC Bulletin Board: INIS) announces ... ending September 30, 2007. REVENUE: Revenue for ... was $1,486,112 and $3,592,049 respectively, as compared to,$1,458,260 ... These numbers,represent an increase of 2% for the ...
... Nov. 12 HLM Venture Partners announced today,that it ... financing of,CaseNET, Inc. CaseNET, based in Waltham, MA, is ... enterprises and government,agencies a software solution for medical and ... $4 million to the round and was joined,by existing ...
Cached Medicine News:Health News:Smac-ing lung cancer to death 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 3Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 3Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 4Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 5Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4Health News:HLM Venture Partners Leads Series B Financing of CaseNET, Inc. 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: